drugset
drugset / Trial / NCT02106988

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988 ↗

Phase 2 Active not recruiting 26 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.

Timeline

Start
2015-01-16
Primary completion
2034-01-31
Completion
2034-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 200 mg/m2 Intravenous
Subject Dexamethasone Small molecule 40 mg Intravenous
Subject Etoposide Small molecule 67 mg/m2 Intravenous
Subject Ifosfamide Small molecule 1 g Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 0.4 g Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 0.6 g Intravenous

Indications

lymphoma